You’ll profit from Pfizer’s new focus

Article Excerpt

Under a new long-term strategy, Pfizer is concentrating on what it does best: developing new patented drugs that generate strong returns for its shareholders. As part of that plan, the company is merging its over-the-counter and generic drugs businesses with those of other pharmaceutical firms to form joint ventures. These deals will cut Pfizer’s risk, and investors will benefit as operating costs fall. The company also plans to eventually hand out shares in the new ventures to its investors. Pfizer’s shares are down 10% since the COVID-19 outbreak. However, the crisis should little impact sales of its current drugs. You should also note that the company is now working on potential vaccines for the coronavirus with German drugmaker BioNTek. If clinical trials are successful, the partners could supply millions of COVID-19 vaccine doses by the end of 2020. That only bolsters your investor value. PFIZER INC. $36 (New York symbol PFE; Manufacturing & Industry sector; Shares o/s: 5.55 billion; Market cap: $199.8 billion; Divd…